Cours suspendu

Communiqués OPTINOSEPAR

Actions

OPTN

US68404V2097

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 20/05/2025			Varia. 5j.	Varia. 1 janv.
9,600 ^USD	-1,13%		-.--%	-

22/05/25	BioPharma Credit reçoit 83 millions de dollars suite à la vente d'OptiNose	MT
21/05/25	Paratek Pharmaceuticals, Inc a finalisé l'acquisition d'OptiNose, Inc. (NasdaqGS : OPTN) auprès d'un groupe d'actionnaires.	CI

Communiqués

21/05/25	Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies	AQ
15/05/25	OptiNose: Q1 Earnings Snapshot	AQ
29/04/25	OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN	BU
26/03/25	OptiNose: Q4 Earnings Snapshot	AQ
26/03/25	Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights	AQ
21/03/25	OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN	BU
20/03/25	OPTN Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of OptiNose, to Paratek Pharmaceuticals	AQ
20/03/25	Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call	AQ
11/03/25	Optinose Announces Reporting Date for Fourth Quarter and Full Year 2024 Financial Results	AQ
15/01/25	Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million	AQ
26/12/24	Optinose Announces 1-for-15 Reverse Stock Split	AQ
02/12/24	Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference	AQ
12/11/24	Optinose : Reports Third Quarter 2024 Financial Results and Recent Operational Highlights Form 8 K	PU
12/11/24	Optinose : Q3 2024 Earnings	PU
12/11/24	Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights	AQ
05/11/24	Optinose Announces Reporting Date for Third Quarter 2024 Financial Results	AQ
16/10/24	Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
08/10/24	Optinose : Appoints Terry Kohler as Chief Financial Officer Form 8 K	PU
07/10/24	Optinose Appoints Terry Kohler as Chief Financial Officer	AQ
06/09/24	Optinose - New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery	AQ
05/09/24	New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery	AQ
26/08/24	Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference	AQ
08/08/24	Optinose : Q2 2024 Earnings	PU
08/08/24	OptiNose: Q2 Earnings Snapshot	AQ
08/08/24	Optinose Reports Second Quarter 2024 Financial Results and Recent Operational Highlights	AQ